RNAi Agents Targeting PLP1 for Pelizaeus-Merzbacher Disease

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a lack of effective treatments for leukodystrophies such as Pelizaeus-Merzbacher disease (PMD), which are characterized by severe symptoms including hypotonia, nystagmus, optic atrophy, and premature death due to overexpression or mutations of proteolipid protein 1 (PLP1).

Innovation Solution

The development of antisense agents, oligomeric compounds, oligomeric duplexes, and RNAi agents that specifically target and reduce the expression of PLP1 RNA in cells, thereby decreasing the amount or activity of proteolipid protein 1 and ameliorating symptoms associated with PMD and other leukodystrophies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If PLP1 is overexpressed due to duplications or triplications, then myelin protein content increases, but toxic gain-of-function occurs leading to dysmyelination and severe symptoms

Engineering Contradiction:

ImprovePLP1 protein contentVSAvoidtoxic gain-of-function effects

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The invention converts the harmful overexpression of PLP1 into a therapeutic target by designing antisense oligonucleotides that specifically bind to PLP1 mRNA, triggering RNA interference to reduce toxic PLP1 protein levels while preserving normal physiological functions

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The antisense oligonucleotides are designed with specific sequence complementarity to target only PLP1 mRNA transcripts, allowing selective reduction of toxic PLP1 protein in affected cells while leaving other myelin proteins and normal PLP1 functions unaffected

Inventive Principle:

Principle #3Local quality

2Object-affected harmful factors

If PLP1 is reduced to eliminate toxic effects, then dysmyelination symptoms improve, but normal myelin function may be compromised

Engineering Contradiction:

Improvedysmyelination symptomsVSAvoidnormal myelin function

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The antisense oligonucleotides are designed to achieve partial reduction of PLP1 expression levels rather than complete elimination, aiming to reduce toxic gain-of-function effects while maintaining sufficient PLP1 levels for normal myelin structure and function

Inventive Principle:

Principle #16Partial or excessive action

Solution Approach 2:

The invention modulates PLP1 expression levels to an optimal range by controlling the dosage and sequence specificity of antisense oligonucleotides, achieving therapeutic reduction of toxic effects while preserving essential physiological functions

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If conventional therapies are used for PMD, then symptom management is provided, but no curative treatment is available leading to premature death

Engineering Contradiction:

Improvesymptom managementVSAvoidcurative treatment outcome

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The invention replaces conventional palliative symptom management approaches with a molecular-level therapeutic mechanism using antisense oligonucleotides to directly target and reduce toxic PLP1 protein expression, addressing the root cause rather than just managing symptoms

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

Antisense oligonucleotides serve as intermediary molecules that bridge the gap between genetic information and protein expression, binding to PLP1 mRNA to prevent translation and thereby reducing toxic PLP1 protein levels without requiring gene editing or other invasive interventions

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These compounds and methods effectively reduce the expression of PLP1, leading to improved symptoms and potentially delaying or slowing the progression of PMD, providing a therapeutic benefit for patients with this severe and fatal disease.

Implementation Method 1

RNAi Agents of Modulating PLP1 SEQUENCE LISTING

Methodology Applied

Scientific EffectRNA interference (RNAi):

Data Source

PatentUS20250197858A1RNAi Agents of Modulating PLP1

Publication Date: 2025.06.19 IONIS PHARMACEUTICALS INC

AI summary

Provided are antisense agents, RNAi agents, pharmaceutical compositions, and methods of use for reducing the amount or activity of PLP1 RNA in a cell or subject, and in certain instances reducing the amount of proteolipid protein 1 in a cell or subject. In certain embodiments, also provided herein are oligomeric compounds and oligomeric duplexes for reducing the amount or activity of proteolipid protein 1 (PLP1) RNA in a cell or subject, and in certain instances reducing the amount of proteolipid protein 1 in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a leukodystrophy. Such symptoms and hallmarks include hypotonia, nystagmus, optic atrophy, respiratory distress, delay in motor function development, cognitive dysfunction, speech dysfunction, spasticity, ataxia, seizures, choreiform movements, and death. Such leukodystrophies include Pelizaeus-Merzbacher disease.